ICD-10-CM 2027 diagnosis code
D68.51Activated protein C resistance
D68.51 is a valid, billable ICD-10-CM code for activated protein c resistance. It can be reported on claims for dates of service from October 1, 2026 – September 30, 2027.
Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS, effective October 1, 2026. Updated September 29, 2026. About our data
About D68.51
D68.51 is the ICD-10-CM diagnosis code for activated protein C resistance. It belongs to category D68 (other coagulation defects), block D65-D69 (coagulation defects, purpura and other hemorrhagic conditions) and chapter 3 (diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.
Within D68.5 (primary thrombophilia), D68.51 is specifically for activated protein C resistance. Related codes cover Prothrombin gene mutation (D68.52) and other primary thrombophilia (D68.59).
As a secondary diagnosis it is a CC (complication or comorbidity), which can move an inpatient stay into the "with CC" MS-DRG of its family, unless the principal diagnosis excludes it.
In MS-DRG v44.0, it is part of the grouping logic for DRG 814 (Reticuloendothelial and Immunity Disorders with MCC, relative weight 2.0729), DRG 815 (Reticuloendothelial and Immunity Disorders with CC, relative weight 1.0444) and DRG 816 (Reticuloendothelial and Immunity Disorders without CC/MCC, relative weight 0.7381), in MDC 16 (Diseases and Disorders of the Blood and Blood Forming Organs and Immunological Disorders), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.
It has been part of ICD-10-CM since the code set took effect on October 1, 2015 and hasn't changed since.
Before ICD-10, this condition was coded in ICD-9-CM as 289.81 (primary hypercoagulable state).
Coding notes
- Factor V Leiden mutation
Notes that apply from higher levels
Instructions written at a parent level also apply to D68.51.
› From D68.5 Primary thrombophilia
- antiphospholipid syndrome (D68.61)
- lupus anticoagulant (D68.62)
- secondary activated protein C resistance (D68.69)
- secondary antiphospholipid antibody syndrome (D68.69)
- secondary lupus anticoagulant with hypercoagulable state (D68.69)
- secondary systemic lupus erythematosus [SLE] inhibitor with hypercoagulable state (D68.69)
- systemic lupus erythematosus [SLE] inhibitor finding without diagnosis (R76.0)
- systemic lupus erythematosus [SLE] inhibitor with hemorrhagic disorder (D68.312)
- thrombotic thrombocytopenic purpura (M31.19)
Broader instructions also apply from Chapter 3: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism.
Alphabetic index entries
5 entriesTerms in the official ICD-10-CM index that lead to D68.51.
MS-DRG v44.0 grouping
All DRGs →Inpatient MS-DRGs this diagnosis can group to, as the principal or a secondary diagnosis, depending on the rest of the claim.
MDC 16 · Diseases and Disorders of the Blood and Blood Forming Organs and Immunological Disorders
ICD-9-CM equivalent
Converter →- 289.81Primary hypercoagulable stateapproximate
From the CMS 2018 General Equivalence Mappings (GEMs), the final GEMs release.
Code history
- 2016
- 2017
- 2018
- 2019
- 2020
- 2021
- 2022
- 2023
- 2024
- 2025
- 2026
- 2027
- FY2016 (effective 10/1/2015): Added (first year of ICD-10-CM)
- No changes since FY2016.
Common questions about D68.51
Is D68.51 billable?
- Yes. D68.51 is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).
Can D68.51 be used as a principal diagnosis?
- Yes. The Medicare Code Editor doesn't restrict D68.51 as a principal diagnosis.
Is D68.51 a CC or MCC?
- D68.51 is a CC (complication or comorbidity) under MS-DRG v44.0, unless excluded by the principal diagnosis.
What DRG does D68.51 group to?
- D68.51 is used in the MS-DRG v44.0 logic for MS-DRG 814 (Reticuloendothelial and Immunity Disorders with MCC), MS-DRG 815 (Reticuloendothelial and Immunity Disorders with CC) and MS-DRG 816 (Reticuloendothelial and Immunity Disorders without CC/MCC). Which one applies depends on whether it is the principal diagnosis and on the rest of the claim.
What is the ICD-9 code for D68.51?
- The CMS General Equivalence Mappings map D68.51 to ICD-9-CM 289.81.